Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells
- PMID: 1873815
Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells
Abstract
An astoundingly high frequency of micrometastatic cells have been found in bone marrow aspirates of patients with colon carcinomas (G. Schlimok et al., J. Clin. Oncol., 8:831-837, 1990), although these tumors very rarely metastasize to the skeleton. This observation has raised questions about the malignant potential of such cells. In a first attempt to characterize this potential, we have assessed the expression of major histocompatibility complex (MHC) class I antigens on bone marrow micrometastases, inasmuch as down-regulation of these molecules is a potential mechanism to escape from MHC class I-restricted lysis by cytotoxic T-cells. The two groups of cancer patients compared were those with tumors known to rarely (stomach and colon cancer) or frequently (breast cancer) manifest skeleton metastases. Bone marrow aspirates taken from these patients were probed for individual disseminated tumor cells using the immunoalkaline phosphatase technique with monoclonal antibody CK2 to the epithelial differentiation antigen cytokeratin 18 (CK-18), as described previously (G. Schlimok et al., Proc. Natl. Acad. Sci. USA, 84:8672-8676, 1987). Specimens containing CK18-positive cells were colabeled with monoclonal antibody W6/32 directed to a framework (or nonpolymorphic) antigenic determinant of MHC class I heavy chains associated with beta 2-microglobulin. W6/32-positive CK-18-positive cells could be detected in 25 of 54 patients (46.3%) with significantly higher incidences in 26 breast cancer patients (61.9%) as compared to 28 patients with carcinomas of the stomach and colon (27.3 and 29.4%). Independent from the origin of the primary carcinoma, the incidence of W6/32-negative CK18-positive cells was positively correlated to both the differentiation grade of the primary tumor (P less than 0.05) and appeared to be linked to the occurrence of regional lymph node metastases (statistically not significant) determined by conventional histological examination. The present results demonstrate for the first time that down-regulation of MHC expression on individual micrometastatic cells correlates to the differential pattern of metastasis obtained by comparing breast and gastrointestinal carcinomas. This finding together with the suggestive link to clinical risk factors supports the significance of reduced MHC class I expression for the survival of residual metastatic cells which is a major determinant of prognosis for patients with solid tumors.
Similar articles
-
MHC-class I antigen expression on micrometastases in bone marrow of patients with head and neck squamous cell cancer.Anticancer Res. 2003 Mar-Apr;23(2B):1467-71. Anticancer Res. 2003. PMID: 12820411
-
Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer.Cancer Res. 1993 Mar 1;53(5):1027-31. Cancer Res. 1993. PMID: 7679945
-
Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas.Cancer Res. 1991 Dec 1;51(23 Pt 1):6372-80. Cancer Res. 1991. PMID: 1933900
-
Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer.Cancer Treat Rev. 2000 Feb;26(1):53-65. doi: 10.1053/ctrv.1999.0150. Cancer Treat Rev. 2000. PMID: 10660491 Review.
-
MHC class I down-regulation: tumour escape from immune surveillance? (review).Int J Oncol. 2004 Aug;25(2):487-91. Int J Oncol. 2004. PMID: 15254748 Review.
Cited by
-
Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy.MedComm (2020). 2023 Dec 2;4(6):e427. doi: 10.1002/mco2.427. eCollection 2023 Dec. MedComm (2020). 2023. PMID: 38045829 Free PMC article. Review.
-
CD8+ T cells are crucial for the ability of congenic normal mice to reject highly immunogenic sarcomas induced in nude mice with 3-methylcholanthrene.Clin Exp Immunol. 2000 Aug;121(2):210-5. doi: 10.1046/j.1365-2249.2000.01292.x. Clin Exp Immunol. 2000. PMID: 10931133 Free PMC article.
-
Immunocytochemical detection and phenotypic characterization of micrometastatic tumour cells in bone marrow of patients with prostate cancer.Urol Res. 1994;22(1):3-8. doi: 10.1007/BF00431541. Urol Res. 1994. PMID: 7521088
-
Editorial: Revisiting seed and soil: A new approach to target hibernating dormant tumor cells.Front Oncol. 2023 Jan 30;13:1126924. doi: 10.3389/fonc.2023.1126924. eCollection 2023. Front Oncol. 2023. PMID: 36798827 Free PMC article. No abstract available.
-
ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients.Breast Cancer Res. 2008;10(5):R76. doi: 10.1186/bcr2143. Epub 2008 Sep 15. Breast Cancer Res. 2008. PMID: 18793387 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials